{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-23-022312","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.585658+00:00","generated_at":"2026-06-16T03:05:03.595154+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"ADMA Biologics amends Hayfin credit agreement, cuts rate by 1%, extends $25M delayed draw loan","bullets":["Interest rate reduced 1% to SOFR + 8.50%; up to 2.50% interest may be paid in kind.","New 50% waiver of prepayment fee on acquisition or strategic transactions within 24 months.","Delayed draw term loan of $25M extended from June 30, 2023 to December 31, 2023.","Issued warrants for 2,391,244 shares at $3.2619 per share, expiring May 1, 2030.","Total debt level unchanged; company cites strengthened financial outlook."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-23-022312","json":"https://secwatch.observer/filing/0001140361-23-022312.json","markdown":"https://secwatch.observer/filing/0001140361-23-022312.md","text":"https://secwatch.observer/filing/0001140361-23-022312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/0001140361-23-022312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/brhc20052223_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T03:05:03.595154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6bf6d9c311609e44c38a5568aebb45a81a4532a1","claim":"ADMA BIOLOGICS, INC. amended Amendment No. 2 with Hayfin Services LLP and the lenders identified therein (effective 2023-05-01).","evidence_excerpt":"On May 1, 2023 (the “Amendment Closing Date”), ADMA Biologics, Inc. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to the Credit Agreement and Guaranty, dated as of March 23, 2022, as previously amended by that certain Amendment No. 1 to the Credit Agreement and Guaranty, dated as of March 22, 2023 (the “Hayfin Credit Agreement”), with Hayfin Services LLP and the lenders identified therein (collectively, “Hayfin”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/0001140361-23-022312-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Hayfin Services LLP and the lenders identified therein"},{"label":"Effective","value":"2023-05-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}